DongKook Pharmaceutical Co. Ltd (KQ:086450) — Market Cap & Net Worth
Market Cap & Net Worth: DongKook Pharmaceutical Co. Ltd (086450)
DongKook Pharmaceutical Co. Ltd (KQ:086450) has a market capitalization of $112.04 Million (₩165.33 Billion) as of June 19, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #18848 globally and #888 in its home market, demonstrating a 3.35% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying DongKook Pharmaceutical Co. Ltd's stock price ₩18810.00 by its total outstanding shares 8789660 (8.79 Million). Review DongKook Pharmaceutical Co. Ltd (086450) financial obligations to assess the company's total debt and financial obligations.
DongKook Pharmaceutical Co. Ltd Market Cap History: 2015 to 2026
DongKook Pharmaceutical Co. Ltd's market capitalization history from 2015 to 2026. Data shows growth from $65.17 Million to $112.04 Million (7.75% CAGR).
Index Memberships
DongKook Pharmaceutical Co. Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$270.08 Billion | 0.04% | #357 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$270.08 Billion | 0.04% | #357 of 1384 |
Weight: DongKook Pharmaceutical Co. Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
DongKook Pharmaceutical Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how DongKook Pharmaceutical Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
DongKook Pharmaceutical Co. Ltd's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.00x
DongKook Pharmaceutical Co. Ltd's market cap is 0.00 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $64.28 Million | $309.69 Billion | $40.66 Billion | 0.00x | 0.00x |
| 2017 | $71.60 Million | $354.77 Billion | $39.60 Billion | 0.00x | 0.00x |
| 2018 | $65.96 Million | $400.81 Billion | $46.95 Billion | 0.00x | 0.00x |
| 2019 | $102.41 Million | $482.28 Billion | $56.31 Billion | 0.00x | 0.00x |
| 2020 | $169.12 Million | $559.10 Billion | $55.93 Billion | 0.00x | 0.00x |
| 2021 | $127.06 Million | $594.19 Billion | $50.35 Billion | 0.00x | 0.00x |
| 2022 | $97.77 Million | $661.65 Billion | $52.90 Billion | 0.00x | 0.00x |
| 2023 | $96.26 Million | $730.99 Billion | $47.18 Billion | 0.00x | 0.00x |
| 2024 | $98.40 Million | $812.17 Billion | $61.22 Billion | 0.00x | 0.00x |
| 2025 | $102.16 Million | $926.88 Billion | $66.02 Billion | 0.00x | 0.00x |
Competitor Companies of 086450 by Market Capitalization
Companies near DongKook Pharmaceutical Co. Ltd in the global market cap rankings as of June 19, 2026.
Key companies related to DongKook Pharmaceutical Co. Ltd by market ranking:
- Sam Chun Dang Pharm. Co. Ltd (KQ:000250): Ranked #4311 globally with a market cap of $3.82 Billion USD ( ₩5.63 Trillion KRW).
- ST Pharm Co.Ltd (KQ:237690): Ranked #7107 globally with a market cap of $1.61 Billion USD ( ₩2.37 Trillion KRW).
- NatureCell Co.Ltd (KQ:007390): Ranked #8654 globally with a market cap of $1.10 Billion USD ( ₩1.63 Trillion KRW).
- Oscotec Inc (KQ:039200): Ranked #10333 globally with a market cap of $755.10 Million USD ( ₩1.11 Trillion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #4311 | Sam Chun Dang Pharm. Co. Ltd | KQ:000250 | $3.82 Billion | ₩263000.00 |
| #7107 | ST Pharm Co.Ltd | KQ:237690 | $1.61 Billion | ₩127000.00 |
| #8654 | NatureCell Co.Ltd | KQ:007390 | $1.10 Billion | ₩30650.00 |
| #10333 | Oscotec Inc | KQ:039200 | $755.10 Million | ₩39650.00 |
DongKook Pharmaceutical Co. Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, DongKook Pharmaceutical Co. Ltd's market cap moved from $65.17 Million to $ 112.04 Million, with a yearly change of 7.75%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩112.04 Million | +9.68% |
| 2025 | ₩102.16 Million | +3.81% |
| 2024 | ₩98.40 Million | +2.23% |
| 2023 | ₩96.26 Million | -1.55% |
| 2022 | ₩97.77 Million | -23.05% |
| 2021 | ₩127.06 Million | -24.87% |
| 2020 | ₩169.12 Million | +65.15% |
| 2019 | ₩102.41 Million | +55.26% |
| 2018 | ₩65.96 Million | -7.87% |
| 2017 | ₩71.60 Million | +11.38% |
| 2016 | ₩64.28 Million | -1.36% |
| 2015 | ₩65.17 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of DongKook Pharmaceutical Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $112.04 Million USD |
| MoneyControl | $112.04 Million USD |
| MarketWatch | $112.04 Million USD |
| marketcap.company | $112.04 Million USD |
| Reuters | $112.04 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About DongKook Pharmaceutical Co. Ltd
DongKook Pharmaceutical Co., Ltd. provides pharmaceutical products in South Korea and internationally. It produces active pharmaceutical ingredients, including propofol, streptokinase, and teicoplanin; disposable syringes; and pills, capsules, and ointments, as well as small volume parentral, large volume parentral, and lyophilized injectable drug injections. The company also offers Teicon, Durak… Read more